SHENZHEN, Jan 30, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need.Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential.The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone's real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred.This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's position in the field of skin health.Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China.About VitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.More About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream2. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar3. The clinical studies information can be found on the Opzelura® official website, as follows:https://www.opzelura.com/opzelura-prescribing-information4. China Insights Consultancy’s industrial reportCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – As China’s first batch of Level 3 (L3) conditionally autonomous driving vehicles receives official market access, advanced smart driving is poised for its inaugural year of commercial explosion. At this pivotal juncture, Cheche Group Inc. (CCG) ("Cheche" or the "Company"), a leading global InsurTech platform, announced the signing of a strategic cooperation agreement with Volkswagen (Anhui) Digital Sales and Services Co., Ltd. (hereinafter "DSSO") and Beijing Cardif Airstar Property & Casualty Insurance Co., Ltd. (hereinafter "Cardif Airstar Insurance").This tripartite collaboration is more than just a deep dive into high-quality growth for New Energy Vehicle (NEV) insurance; it represents a core transition from "digitization" to "intelligence." The partnership establishes three strategic directions for synergy. First, it focuses on the transformation of product formats by leveraging Cheche’s SaaS platform to co-create an integrated "Insurance + Value-Added Services" package, enabling the efficient, one-stop fulfillment of high-value services. Second, it upgrades pricing capabilities by deeply integrating compliant driving data with dynamic vehicle information, utilizing AI-driven risk profiling to achieve differentiated precision pricing while addressing the complex challenge of liability determination in human-machine co-driving scenarios. Finally, it expands the ecosystem dimension by embedding insurance services throughout the vehicle sales and after-sales process, extending the business from a single policy to a full-lifecycle service ecosystem that encompasses renewal management and mobility protection.01. Smart Driving Insurance: Securing "Pricing Authority" in the L3 Mass Production EraTraditional auto insurance has long struggled with "human-machine co-driving" scenarios due to a lack of real-time dynamic data for liability determination and precise risk identification. Having served leading automakers such as Tesla, Li Auto, and Xiaomi, Cheche provides VW Anhui Digital with an embedded SaaS system centered on data attribution and dynamic pricing.Through this SaaS infrastructure, vehicle driving data is seamlessly synchronized with BNP Paribas Star’s actuarial models. This AI-driven joint risk profiling not only resolves the technical difficulties of liability judgment in smart driving scenarios but also delivers a "low-premium rewards for safe drivers," serving as a vital solution to the profitability challenges currently facing the NEV insurance industry.02. Ecosystem Breakthrough: Leveraging the "Xiaomi + Volkswagen DSSO" New Quality Productive ForcesInvestors are closely watching the cross-sector dynamics underpinning this collaboration. Cardif Airstar Insurance was co-founded by Xiaomi Group, Volkswagen Financial Services, and Cardif Airstar Insurance, combining the strengths of an internet giant, a global financial powerhouse, and a leading smart automaker.As the hub connecting these forces with Volkswagen’s Hefei Intelligent Electric Vehicle Center, Cheche is penetrating the world’s top smart driving supply chains. This is not merely system integration; it marks Cheche’s evolution into a digital operator within the "Vehicle-Battery-Charging-Insurance" integrated landscape. Amid policy tailwinds such as "New Quality Productive Forces," Cheche’s closed-loop ecosystem is becoming a definitive growth pole for insurance and tech capital.03. Scenario Transformation: From Transactional Policies to Full-Lifecycle OperationsIn 2026, as the automotive market shifts from a competition over hardware parameters to a competition over user experience, Cheche is helping DSSO deeply couple insurance services with the car-buying and after-sales journey. The integrated service package transforms insurance from a low-frequency tool into a high-frequency touchpoint for user engagement.Christian Koenig, After-sales Director of DSSO, noted that Cheche’s technical foundation allowed the partnership to advance rapidly from a high starting point. This "plug-and-play" empowerment capability, proven by mainstream automakers, has become a technical moat for Cheche in the capital markets.04. Conclusion: The Final Piece of the Trillion-Dollar Blue OceanThe year 2026 marks the point where NEV insurance evolves from scale expansion to intelligent upgrades. Cheche will continue to advance its AI pricing engine, driving the leap from digital to intelligent services.According to data released by the Ministry of Public Security on January 26, China’s NEV ownership reached 43.97 million units by the end of 2025, accounting for 12.01% of the total vehicle population—a growth rate exceeding 40% year-over-year. In this environment, those who define the insurance standards for the smart driving era will control the entry point to future mobility. With its high barriers to entry via OEM partnerships and forward-looking AI layouts, Cheche is racing toward becoming a leader in the trillion-dollar NEV insurance market. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – 27 January 2026, Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) announced its continued support for elite athletes from The Education University of Hong Kong (“EdUHK”) for the fourth consecutive year. The Presentation Ceremony for the Nissin Foods Scholarship for Elite Athletes 2025/2026 was held to honour seven outstanding athletes who not only demonstrate excellence in their respective sports but also aspire to become future educators. The scholarship will cover their full tuition fees throughout their entire study period, enabling them to pursue their academic and athletic goals without financial concerns.Established in 2022 by the Nissin Foods (Hong Kong) Charity Fund, the scholarship is designed to encourage elite athletes enrolled in the Bachelor of Health Education (Honours), Bachelor of Science (Honours) in Sports Science and Coaching, or the Postgraduate Diploma in Education programme at EdUHK. The initiative aims to support their dual career development, empowering them to become qualified health educators while continuing to strive for excellence in their athletic performance.The seven awardees for the 2025/2026 academic year include new and renewing recipients. The four new awardees are: Mr. MOK Pak Fan (triathlon), Mr. WONG Pak Yiu (triathlon), Miss HO Kin Yiu (volleyball), and Miss YAN Nuo (shuttlecock). In addition to welcoming new scholars, the Charity Fund also made the scholarship renewable to support the elite athletes throughout their study period. The three recipients of the renewed scholarship are: Mr. CHOI Kwan Lok (cycling, retired), Mr. CHEN Pak Hong (rowing), and Mr. Joseph LAU (cycling).Mr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund, said, “Having been deeply rooted in Hong Kong for over four decades, Nissin Foods is steadfast in its mission to give back to the community. This scholarship is a direct reflection of our founder Mr. Momofuku Ando’s philosophy that ‘Eating and sports are the two axles of health.’ By supporting these talented athletes at EdUHK for the fourth year, we are not just providing financial support, we are investing in future leaders who will champion health and wellness in our society. We are proud to empower them on their dual career path, confident that they will inspire the next generation as both accomplished athletes and dedicated educators.”Expressing his profound gratitude for the long-standing partnership, Professor Chetwyn CHAN, Vice President (Research and Development) of EdUHK, said, “EdUHK is dedicated to promoting sustainable dual-career pathways for high-performance athletes. The generous Nissin Foods Scholarship for Elite Athletes allows us to support both active and retired athletes in advancing their educational pursuits, while also recognising their exceptional sporting accomplishments. I would like to extend my heartfelt congratulations to all the scholarship recipients, who demonstrated great passion, determination, and a sense of mission, and sincerely thank the Nissin Foods (Hong Kong) Charity Fund, and Mr Ando for the tremendous support and confidence in health education and the development of elite athletes.”Accomplished volleyball player Miss HO Kin Yiu, recipient of the scholarship from the Postgraduate Diploma in Education, majoring in Chinese and Physical Education, shared her heartfelt appreciation to the Charity Fund, “The support of the scholarship empowers us, as elite athlete-students, to chase our aspirations and make a meaningful influence on society. We are confident that we can help create a brighter future through the spirit of sports and education.”PhotoMr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund (middle right), and Professor Chetwyn CHAN, Vice President (Research and Development) of EdUHK (middle left), attended the Presentation Ceremony for Nissin Foods Scholarship for Elite Athletes 2025/2026 on 27 January 2026. Five scholarship recipients attended the ceremony, including four new awardees for the 2025/2026 academic year, namely: (from left to right) Mr. MOK Pak Fan, Mr. WONG Pak Yiu, Miss HO Kin Yiu, and Miss YAN Nuo, as well as the renewed awardee - Mr. CHOI Kwan Lok. Awardees of the Nissin Foods Scholarship for Elite Athletes 2025/2026 are achieving great success in their individual disciplines. From top left: Mr. WONG Pak Yiu (triathlon), Miss HO Kin Yiu (volleyball), Mr. MOK Pak Fan (triathlon), Miss YAN Nuo (shuttlecock), Mr. CHOI Kwan Lok (cycling, retired), Mr. CHEN Pak Hong (rowing), and Mr. Joseph LAU (cycling).About Nissin Foods (Hong Kong) Charity FundThe Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) was set up in September 2020 by way of a trust deed by Nissin Foods Company Limited (Stock code: 1475). The objectives of the Charity Fund are: a) to advance education, teaching, learning, arts, science and academic research; b) to make provision for people in need; and c) to carry out works of a charitable nature that are beneficial to the Hong Kong community. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

PUTNAM, CT AND ROMEOVILLE, IL, Jan 29, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra and GEON® Performance Solutions today announced an agreement that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in Europe. This adds to Formerra's current distribution of these materials in North and South America, enabling Formerra to now support customers who need the same product in all regions.Following GEON's January 2025 acquisition of Foster, the agreement builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials."Bringing Foster's medical-grade portfolio to Europe strengthens our ability to support healthcare manufacturers across the region with specialized compounds and the local expertise they need to navigate complex regulatory environments," said Kelly Wessner, Vice President, Key Accounts, Formerra. "Building on the momentum of our Americas partnership, we're excited to extend these proven solutions to European customers who demand the highest standards in medical device materials."With more than 30 years in custom medical polymer compounding, Foster delivers highly engineered, top-of-the-polymer-pyramid formulations tailored to demanding requirements. The portfolio includes options such as radiopaque compounds and grades that meet USP Class VI requirements and align with ISO 10993 expectations. These materials support critical end uses across the healthcare space, including implantable products and other highly specialized applications."Extending our Foster portfolio into Europe with Formerra allows us to meet growing demand from healthcare manufacturers in one of the world's most dynamic medical device markets," said Arthur Adams, Chief Commercial Officer, GEON. "This expansion reinforces our shared commitment to supporting innovation in life-saving applications globally."Adding Foster® compounds to its European portfolio will enable Formerra to better serve customers in the healthcare space, offering not only access to highly engineered medical polymers, but also deep regulatory expertise and responsive logistics across the region.Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, February 3-5, 2026.Key DetailsFormerra will distribute Foster® medical compounds in Europe.This agreement adds custom medical-grade compounds to Formerra's existing global access to GEON® PVC and filled PP materials.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.About GEON Performance SolutionsGEON® Performance Solutions unlocks the power of polymers for the future. From biomedical materials from our medical division, Foster, LLC, to building materials, automotive, connectivity, and appliances, customers in these markets rely on the portfolio of compounding solutions, highly adaptable vinyl, polyolefin, engineered resin technologies, and full-service contract manufacturing that we deliver. In every formulation, collaboration, and challenge we're shaping the brilliance of tomorrow and providing a formidable advantage by engineering what's possible. Geon has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Learn more at www.geon.com. Geon is a portfolio company of SK Capital Partners.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – A growing number of robotics and artificial intelligence companies backed by Shoucheng Holdings Limited are set to appear at China’s 2026 CMG New Year’s Gala, reflecting the investor’s expanding footprint across the country’s emerging automation and embodied intelligence sectors.The latest company to confirm its participation is Noetix Robotics, according to recent announcements. Shoucheng Holdings led the company’s financing round in 2024 and has continued to increase its investment through subsequent rounds, making it Noetix Robotics’ largest external investor, people familiar with the matter said.Noetix Robotics’ appearance adds to a lineup that already includes other Shoucheng-backed firms. Unitree Robotics, known for its quadruped and humanoid robots, was earlier named a robot partner of the 2026 Gala, marking its third appearance on the program. Beijing Galbot Co., Ltd., which focuses on embodied artificial intelligence systems, has also been designated by China Media Group as the Gala’s embodied large-model robot.The clustering of multiple portfolio companies on the same edition of the Gala places Shoucheng Holdings among a small group of investors with broad representation on one of China’s most-watched annual broadcasts. The event, which regularly draws hundreds of millions of viewers, has increasingly been used as a platform to highlight advances in artificial intelligence, robotics and advanced manufacturing.China Media Group, the organizer of the Gala, has in recent years expanded the role of technology-focused programming, aligning with national policy priorities around intelligent manufacturing and industrial upgrading. While participation in the Gala does not directly translate into revenue, companies and investors see it as an important signal of technical maturity and policy relevance.Unitree Robotics’ repeated appearances underscore this dynamic. The company has previously used the Gala to demonstrate improvements in motion control, balance and coordination, capabilities that are critical as robots move from laboratory environments into commercial and industrial settings. Its continued inclusion suggests confidence in its engineering progress and deployment readiness.Galbot’s designation as the Gala’s embodied large-model robot reflects a broader shift in focus from mechanical performance alone to systems that integrate perception, reasoning and physical execution. Embodied artificial intelligence—where large models are combined with real-world robotic interaction—has become a priority area for Chinese research institutions and technology companies as generative AI expands beyond software applications.The addition of Noetix Robotics introduces another layer to the lineup. The company concentrates on robotic power systems and core engineering components, segments that are increasingly viewed as strategic as China seeks to reduce reliance on imported technologies and strengthen domestic supply chains. Shoucheng Holdings’ sustained backing of Noetix Robotics highlights an investment strategy that spans both complete robotic systems and foundational hardware.Shoucheng Holdings has steadily increased its exposure to robotics over the past several years, backing companies involved in full-stack robotics, embodied intelligence and critical components. Rather than focusing on a single technological approach, the firm has adopted a portfolio strategy that combines capital investment with access to application scenarios and commercialization platforms.One such platform is the Shoucheng Robot Tech Experience Store, a robotics-focused retail and demonstration network operated by the company. While not all Gala participants are Shoucheng investees, some companies, including MagicLab Robotics Technology (Wuxi) Co., Ltd., have placed products such as robotic dogs within the platform’s offline spaces for demonstrations and user engagement. MagicLab was named a strategic intelligent robotics partner for the Year of the Horse CMG New Year’s Gala earlier this year.By linking high-profile media exposure with physical demonstration and sales environments, Shoucheng Holdings aims to accelerate the transition from technology showcase to market adoption, according to people familiar with the platform’s positioning. The approach mirrors a broader trend among Chinese industrial investors to combine financial backing with scenario-based deployment.Industry analysts say the concentration of Shoucheng-backed companies on the 2026 Gala stage illustrates how China’s robotics sector is evolving from isolated prototypes toward more integrated industrial ecosystems. The presence of companies spanning full robotic platforms, embodied intelligence and core engineering components suggests increasing specialization and coordination across the value chain.As preparations for the 2026 CMG New Year’s Gala continue, robotics and artificial intelligence are expected to remain central themes. For Shoucheng Holdings, the event offers a snapshot of how its investments are converging on a national platform, reflecting a strategy that has shifted from selective bets to a broader, system-oriented approach to industrial technology.While the commercial impact of Gala exposure is difficult to quantify, market participants increasingly view the lineup as an indicator of which technologies and companies are gaining momentum within China’s rapidly changing AI and automation landscape. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – Quam Plus International Financial Limited ("Quam Plus Financial" or the "Group") is delighted to announce the successful conclusion of the "3rd Hong Kong Capital Markets Forum 2026" held at the Grand Hyatt Hong Kong. The Group is honored to be one of the Gold Sponsors of this prestigious event. Dr. Kenneth Lam, CEO of the Group, who also serves as Chairman of the Forum Organizing Committee cum Executive Deputy Chairman of The Chamber of Hong Kong Listed Companies (CHKLC), led a delegation of senior management to attend the forum. Mr. Paul Chan Mo-Po, GBM, GBS, MH, JP, Financial Secretary of the Government of HKSAR were also in attendance. Together with prominent figures from the capital markets, government, academia, and the financial sector, they engaged in in-depth discussions on further strengthening Hong Kong's economic momentum.The forum was jointly organized by Hong Kong Association of Registered Public Interest Entity Auditors Limited (PIEAA), The Chamber of Hong Kong Listed Companies (CHKLC), The Hong Kong Institute of Directors (HKIoD), and the Association of Hong Kong Capital Market Practitioners Limited (HKCMP), with strong support from key institutions including Hong Kong Exchanges and Clearing Limited (HKEX), the Securities and Futures Commission (SFC), and the Accounting and Financial Reporting Council (AFRC).As the global economy enters a new cycle of innovation and transformation, this year's forum, themed "Capturing the Next Growth Momentum” explored how Hong Kong can reinvent itself amid a rapidly changing international financial landscape, rebuild confidence, and transform challenges into powerful drivers of progress.As the globalMr. Paul Chan Mo-Po, GBM, GBS, MH, JP, served as the Guest of Honour and delivered the keynote address. He stated: "In my view, the global environment is shifting in ways that create new and favourable opportunities for Hong Kong. Our challenge is how to seize the moment and deliver tangible outcomes. More specifically, that involves supporting the country's high-quality development; matching the needs of Mainland enterprises going global and the appetite of international investors; and, at the same time, driving Hong Kong's own growth."Dr. Kenneth Lam, in his capacity as Chairman of the Forum Organizing Committee, delivered the opening remarks: "As a vital financial hub connecting China and the world, our mission is to strengthen confidence, deepen integration, and expand diverse growth engines. We must keenly identify the next wave of growth drivers and ensure that markets advance in a balanced manner between flexibility and integrity. Positioned at the core of global transformation, this forum reminds us once again that progress is never accidental—it stems from resolute choices: with innovation as our aspiration, collaboration as our bridge, and conviction as our strength, we can lead Hong Kong forward and open up new chapters."Hong Kong now stands at the heart of global change. Advancing the capital markets requires not only visionary policies and regulation but also active participation and collaboration from all sectors. This year's forum focused on two key themes—digital asset development and capital market structural reform—examining how technological innovation can coexist with trust to drive reforms that build greater market resilience.As a proud Gold Sponsor of this year's forum, Quam Plus Financial looks forward to working hand in hand with all stakeholders, including central government offices in Hong Kong and other parties, to propel Hong Kong and the region toward new achievements. Together, we aim to seize new opportunities, activate new momentum, and march toward a high-quality, sustainable financial future.About Quam Plus International Financial LimitedQuam Plus International Financial Limited (the “Company”, Stock Code: 00952.HK) is a Hong Kong based financial services group which is listed on the Main Board of the Stock Exchange of Hong Kong Limited. The Company was publicly listed in Hong Kong in 1997, it is committed to building a comprehensive, full-licensed integrated financial platform. The core businesses of the Company are brokerage business, interest income business, corporate finance business, asset management business and investments and other businesses. The Company strives to become the ideal partner for both corporate and individual investors in Hong Kong and China. The Company also offers premier one-stop financial services to its clients. The Company continued to provide capital markets services through its representative office or the wholly-owned foreign enterprise in Shenzhen, Shanghai, Shenyang, Ningbo, Beijing, Chengdu, Hangzhou and Xiamen of the PRC and through its networks of Global Alliance Partners network and Oaklins International.For further information, please contact:Quam IR LimitedMandy Lo Tel: (852) 2217-2753 Email: mandy.lo@quamgroup.comCharlie Chan Tel: (852) 2217-2504 Email: charlie.chan@quamgroup.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TOKYO, Jan 30, 2026 - (JCN Newswire via SeaPRwire.com) - Anime Tokyo Station (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo) is an anime exhibition facility dedicated to Japanese anime content, which has developed a passionate fan base both in Japan and abroad. Since its opening, the venue welcomed over 250,000 visitors from around the world.Led by the concept of rediscovering the appeal of anime, Anime Tokyo Station has expanded its presence to Roblox, one of the world’s leading immersive platforms, through the release of ANIME TOKYO STATION ON ROBLOX, a hub with interactive games that allow players to explore the charm of Japanese anime and the world of Anime Tokyo Station itself. This Roblox hub has already been visited by over 630,000 players. To commemorate the hub's one-year anniversary, Anime Tokyo Station will be making various updates and giving out free gifts. In addition to giving out free "Shoulder-Perched Cat Train Conductors" that players can use to customize their avatars, the ANIME☆OTODAMA game will be expanded with a new "Momotaro" scenario and the ANIME☆SKILL TCG will be getting new cards, a new ADR timing minigame, and a new undersea passage area. Furthermore, Anime Tokyo Station will also be giving out in-game badges to commemorate the 1st anniversary of the hub's release and, in conjunction with this badge give-away, it will also be handing out exclusive gifts in the real-world Anime Tokyo Station.Please take this opportunity to enjoy Anime Tokyo Station in both the metaverse and the real world.For more information on how to play the game and upcoming version updates, please visit the ANIME TOKYO STATION ON ROBLOX special page within the Anime Tokyo Station website.ANIME TOKYO STATION ON ROBLOX special page: https://animetokyo.jp/en/roblox/Title:ANIME TOKYO STATION ON ROBLOXUpdate date:January 30, 2026, at 10:00 a.m.(JST)Platform:Roblox (iOS, Android, PC, PlayStation5, PlayStation4, Xbox One)Genre:Party gameURL:https://www.roblox.com/games/85319291338189/*You will need to download the Roblox app and register an account to access the game. One-Year Anniversary Project(1) The first 2,000 people to complete the mission will receive "Shoulder-Perched Cat Train Conductors" (free UGC)The first 2,000 players to complete the mission that unlocks at 10:00 a.m. on Friday, January 30, 2026 will receive free UGC that they can use to customize their player visuals!Perch this cute cat train conductor that welcomes visitors to ANIME TOKYO STATION ON ROBLOX on your avatar's shoulder.(2) Momotaro is coming to ANIME☆OTODAMA, along with a new shop!Momotaro, a superhero from the world of Japanese fairy tales, is coming to the world of ANIME☆OTODAMA. Collect the special otodamas to unlock the dog, monkey, pheasant, and ogre of the Momotaro story. Enjoy watching the kind of spectacle you can only expect from Anime Tokyo Station, a facility dedicated to showcasing the appeal of anime.Two ANIME☆SKILL TCG shops will also be opening up: Kinema Club and Anime TAIZEN. Here, you can buy items to make the game even more fun.(3) A new minigame, map, and skill cards in ANIME☆SKILL TCGNew skill cards and character cards will be added to ANIME☆SKILL TCG, which launched last November. Now players can have even more fun in the world of anime production. There will also be a new minigame, the ADR Timing Game, where players can collect the coins they'll need to get new cards. The map will feature a new undersea passage, creating an even larger game world for players to explore.ADR Timing GameHow to play:Tap when the 〇 and 〇 line up! If your ADR is successful, your score will rise. Shoot for a high score to collect special cards and coins!(4) All players will receive a commemorative badge celebrating the one-year anniversary!Everyone who visits ANIME TOKYO STATION ON ROBLOX will receive a commemorative badge to celebrate the hub's one-year anniversary. These badges will only be given out until March 31, so make sure to come by and get one.(5) Free pouches will be given out at the real-world Anime Tokyo StationVisitors to the real-world Anime Tokyo Station, located in Ikebukuro, Tokyo, will receive exclusive pouches when they present a one-year anniversary commemorative badge that they received in-game in (4).Pouches will be given out until Tuesday, March 31, but supplies are limited. Take this opportunity to visit Anime Tokyo Station in person and get one before they're all gone.Information on Version Updates and Release CampaignsFor information on gift campaigns within Roblox and upcoming version updates, please visit the official website and official X account.Special website page: https://animetokyo.jp/en/roblox/Official X account: https://x.com/animetokyo_info (@animetokyo_info)What is Roblox?As of the end of December 2024, Roblox is the world's fastest-growing immersive social platform. It is available in 190 countries and 16 languages, and has roughly 90 million daily active users (as of November 2024). It is particularly popular with young people. Users spend an average of 2.4 hours a day in Roblox, and total play time is on the rise, increasing 24% year-on-year. In Roblox, users can enjoy both gaming and social features. It is particularly popular in the U.S. and Canada, and in Asia, is rapidly growing in Japan and India. Its Japanese user base has grown 56% year-on-year. Roblox is also starting to be used for education, business, and community revitalization, and expectations are high for its continued future expansion.Venue OverviewName:Anime Tokyo Station (also known as "Anime Tokyo")Location:Floors B1 to 2F of Tokyu East 5 (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo)*4 minutes on foot from Ikebukuro StationHours:11:00 a.m. to 7:00 p.m. (last admission: 6:45 p.m. last admission for special exhibitions: 6:30 p.m.)Closed: Mondays*If Monday falls on a holiday, the venue will be open on Monday and closed on the following dayNew Year's holiday periodMay be closed on other daysPlease check the venue website before coming.Admission fee:FreeWebsite:https://animetokyo.jp/en/SNS：X｜https://x.com/animetokyo_info (@animetokyo_info)Instagram｜https://www.instagram.com/animetokyostation/(@animetokyostation)YouTube｜https://www.youtube.com/@AnimeTokyoStationInquiries regarding this press releasePublic Relations Office of "Anime Tokyo Station" (Kyodo PR)Contact person: Miri YasudaE-mail: animetokyo-pr@kyodo-pr.co.jp Press release: https://www.acnnewswire.com/docs/files/20260130.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

NEEDHAM, MASS., Jan 29, 2026 - (ACN Newswire via SeaPRwire.com) — Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, today issued a corporate update summarizing previously disclosed program developments and reinforcing the Company’s strategic direction entering 2026. (BioXyTran)Corporate Update Highlights (Previously Disclosed)ProLectin‑M (broad-spectrum antiviral platform)Bioxytran’s lead antiviral program, ProLectin‑M, is being developed under an active U.S. FDA Investigational New Drug (IND) framework, as previously announced by the Company. In October 2025, the Company announced the completion of a randomized, double-blind, placebo-controlled clinical trial for ProLectin‑M and stated that data from the trial is expected to help inform Phase 3 trial design and be submitted to regulators pursuant to prior regulatory interactions. (BioXyTran)In May 2025, Bioxytran also announced completion of dose optimization work intended to support additional clinical trial planning and agency submissions. Oxygen transport platform (stroke and neurodegenerative diseases)Bioxytran continues to advance its oxygen-transport platform, including development efforts related to a universal oxygen carrier (UOC) and associated measurement/analytical approaches previously described by the Company, including use of the MDX Viewer, which the Company has described as an FDA-approved device to measure tissue oxygenation. In July 2024, Bioxytran announced a joint venture with the Heme Foundation to develop a universal oxygen carrier as an alternative to blood transfusions, including public statements regarding a pledged level of support and reported development progress at that time. Oncology research (Galectin Science)In January 2025, the Company announced a cancer-focused preprint exploring galectin‑3 modulation as a potential strategy to improve response to immune checkpoint inhibitors. (Nasdaq)Management Commentary“Bioxytran enters 2026 with real momentum across our platforms,” said David Platt, Ph.D., Chief Executive Officer of Bioxytran. “Across virology and oxygen transport, our team has stayed focused on disciplined execution—building the data package, advancing the regulatory pathway, and expanding the scientific foundation that supports our programs. We believe our carbohydrate-based approach and galectin science position Bioxytran to pursue meaningful clinical and strategic opportunities as we continue to move forward.” Disclosure NoteThis release is intended as a general corporate update and summarizes information that has been previously disclosed in Company press releases and public filings.About Bioxytran, Inc.Bioxytran is a clinical-stage pharmaceutical company developing platform technologies in glycovirology, hypoxia and degenerative diseases using carbohydrate drug design, including programs that leverage galectin inhibition and programs that aim to address hypoxic conditions and tissue oxygenation. Bioxytran’s common stock trades on the OTCQB under the symbol BIXT.Company Contact:Bioxytran, Inc.75 Second Avenue, Ste 605, Needham, MA 02494Phone: 617‑454‑1199Email: info@bioxytraninc.com Web: www.bioxytraninc.com Forward-Looking StatementsThis press release contains forward-looking statements, including statements regarding anticipated regulatory interactions, future clinical trials, trial designs, timing of data submission and publication, and potential therapeutic and commercial opportunities. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are urged to review the Company’s risk factors disclosed in its reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10‑K for the year ended December 31, 2024. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Jan 29, 2026 - (ACN Newswire via SeaPRwire.com) - LEGENDARY HUMANITY, a Singapore-based company listed on Gate.io, has announced the launch of the "$VIVI RWA MARKET," a new Real World Asset (RWA) marketplace enabling the purchase of exhibited works by contemporary artist Mago Nagasaka. Developed in collaboration with the MAGO Moon Museum, this launch marks a significant milestone in LEGENDARY HUMANITY's ongoing efforts to bridge cultural value and digital infrastructure through real-world assetization.Digitalizing Humanity's Masterpieces Through AI 3D Scanning Technology - A New Purchasing Experience Led by LEGENDARY HUMANITYLEGENDARY HUMANITY PTE. LTD. (Headquarters: Singapore; CEO: Takamasa Suzuki) has officially opened the "$VIVI RWA MARKET," an RWA marketplace where visitors can directly purchase artworks exhibited in the online museum "MAGO Moon Museum," created by contemporary artist Shingo Nagasaka.This initiative forms part of the "VIVI PROJECT," which aims to digitize humanity's masterpieces into digital assets through high-precision, non-contact AI-integrated 3D scanning technology.Through this platform, visitors are able to acquire artworks they have viewed within MAGO Moon Museum as RWAs, enabling a deeper engagement with the artist's worldview and creative philosophy.OverviewName: $VIVI RWA MARKETOpening Date: Thursday, January 29, 2026URL: https://mondo.lhvivi.io/ About "$VIVI RWA MARKET"The "$VIVI RWA MARKET" is an RWA marketplace dedicated to the acquisition of artworks and is embedded within the online museum MAGO Moon Museum.Seamless Pathway from Viewing to PurchaseUsers can seamlessly transition from an artwork's exhibition page to its corresponding RWA product page, creating a unified experience from online viewing to ownership.Integration of Physical and Digital Asset DesignEach artwork includes the following structured information:Physical artwork details (size, materials, condition, provenance)High-resolution digital data generated through AI 3D scanningArtist profile and project background informationalong with other curated metadata.This structure allows users to acquire artworks with a proper understanding of their cultural and artistic value.Ecosystem Holding FunctionalityAcquired works will gradually gain viewing and management functionality within the VIVI ecosystem. While future integration with VIVI COiN is under consideration, the current initiative is focused solely on enhancing the preservation, appreciation, and understanding of the artworks.About LEGENDARY HUMANITY and the VIVI PROJECTLEGENDARY HUMANITY promotes the "VIVI PROJECT," which digitizes legendary masterpieces created by humanity into digital assets using high-precision, non-contact, AI-integrated 3D scanning technology. The project operates under the vision of "Bringing the beauty of humanity to AI and the future."Targeted assets include:Legendary fashion collectionsHistorical architecture and cultural masterpiecesFamous trading cardsArtworks, including those exhibited at MAGO Moon Museumand other assets that can be described as humanity's masterpieces.The VIVI PROJECT aims to:Digitize assets as digital cultural heritageTokenize them as RWAs for global circulationExhibit them in both online and physical museumsthereby building new infrastructure that harmonizes cultural and economic value.NEXT SOCIETY (Gacha Location): https://nextsociety.lhvivi.ioRWA Market RoadmapThe launch of the "$VIVI RWA MARKET" represents the first phase of RWA market functionality within the VIVI PROJECT. Planned future developments include:VIVI FASHION (RWA for the fashion domain)VIVI TRADING CARD (RWA for the trading card domain)VIVI ART WORK (RWA for art collections)with future integration under consideration.About MAGO Moon MuseumMAGO Moon Museum is an online museum created by contemporary artist Shingo Nagasaka, whose works explore themes related to electronic waste issues in Agbogbloshie, Ghana.The museum provides an online space to view Nagasaka's representative works, including pieces created from discarded electronic components found in Ghanaian slums, as well as series examining the concept of "Sustainable Capitalism."With the implementation of the "$VIVI RWA MARKET," viewers can deepen their understanding of the artworks while acquiring pieces aligned with the artist's philosophy in an appropriate and structured manner.Future DevelopmentsBuilding on this initiative, LEGENDARY HUMANITY plans to:Expand collaborations with masterpieces across different regions and genresStrengthen international networks with artists, collectors, and researchersAdvance technological development for the preservation of cultural assets for future generationsand continue developing as a platform that passes humanity's masterpieces into the future through real-world assets.Media ContactCompany Name: LEGENDARY HUMANITY PTE. LTD.Address: 105 Cecil St, The Octagon 24F-2, Singapore 06953Representative: Takamasa Suzuki, LEGENDARY HUMANITY / VIVI PROJECT Public Relations DeskEmail: info@lhvivi.com Related URL: $VIVI RWA MARKET https://mondo.lhvivi.io Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HIROSHIMA, Japan, Jan 29, 2026 - (JCN Newswire via SeaPRwire.com) - Mazda Motor Corporation (Mazda) today announced that cumulative global production and sales of the Mazda CX-5 have both reached five million units as of the end of 2025. This milestone makes the third Mazda model to surpass the five-million-units, following the Mazda323 and the Mazda3. Among Mazda vehicles that fully incorporate the SkyactivTechnology and "Kodo - Soul of Motion", the CX-5 reached this landmark in the shortest time.To date, the CX-5 has been sold in more than 100 countries and regions worldwide. It continues to be chosen by customers across the globe as Mazda's crossover SUV, carrying forward and further refining its vibrant, sporty design and effortless driving experience.Upper section: Left First-generation "CX-5", Right Second-generation "CX-5"Lower section: Third-generation New "CX-5"Since production of the first-generation CX-5 began at the Ujina Plant No.2 in 2011, Mazda has expanded its manufacturing footprint to Ujina Plant No.1, the Hofu Plant*1, and facilities in China. Local assembly *2 has also been carried out in Malaysia and Vietnam, allowing the CX-5 to grow into the best-selling model *3 in Mazda's current lineup. The all-new CX-5 was unveiled in Europe in July 2025. Following its European debut, it will be launched in North America and Japan in spring 2026.Koichiro Yamaguchi, Program Manager for the CX-5, commented: “We would like to express our sincere gratitude to all customers and fans around the world who have supported the CX-5. The all-new CX-5 has been fully changed in eight years, further refines its sporty design and driving dynamics. It offers a spacious cabin where all passengers can enjoy comfort and ease, along with a redesigned Human-Machine Interface*4. Meticulously focused on daily usability, it has evolved into a new-generation SUV that makes driving more comfortable and life itself richer. We will continue to nurture the CX-5 carefully, aiming for it to be cherished for years to come.”Mazda will continue to pursue the "Joy of Driving" and create cars loved by customers under its core value of Radically Human, and aim to deliver the "Joy of Living" by creating moving mobility experiences in the daily lives of its customers.History of the MAZDA CX-5First-generation of the CX-5September 2011World premiere at the “2011 Frankfurt Motor Show”. *5November 2012Won the Japan Car of the Year award.January 2013Ranked first in domestic SUV sales in Japan for 2012. *6January 2014Ranked first in domestic SUV sales in Japan for 2013. *6April 2015Achieved one million units in cumulative global production.Second-generation of the CX-5November 2016World Premiere at the “Los Angeles Auto Show”.February 2022For the ninth consecutive year, the model earned the highest safety rating, “IIHS TOP SAFETY PICK+,” in evaluations conducted by the Insurance Institute for Highway Safety (IIHS).Third-generation CX-5July 2025Unveiled in Europe.October 2025The All-new CX-5 was exhibited for the first time to visitors at the “Japan Mobility Show 2025 (European specification vehicle)”. *1 Production is not currently carried out at the Hofu Plant.*2 Changan Mazda Automobile Co., Ltd. (CMA) produces the CX-5 in China. Locally assembled units in Malaysia (Mazda Malaysia Sdn. Bhd.) and Vietnam (Vina Mazda Automobile Manufacturing Co., Ltd.) are counted as part of domestic production.*3 The bestselling model in Mazda’s product lineup since 2018.*4 It is a generic term referring to a method of exchanging information between humans and machines, as well as the devices and software used for this purpose.*5 The official name is “64th Internationale Automobil-Ausstellung”.*6 According to Mazda. SUVs refer to domestic vehicles classified as off-road 4WD (including some 2WD models) by the Japan Automobile Dealers Association. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

HONG KONG, January 29, 2026 - (ACN Newswire via SeaPRwire.com) – Standard Chartered and the Hong Kong Trade Development Council (HKTDC) have jointly released the latest Standard Chartered Greater Bay Area Business Confidence Index (GBAI), which revealed thatthe business sentiment for most companies in the Greater Bay Area (GBA) remained steady amid persistent external uncertainties in Q4-2025.Following a rebound in the previous quarter, the GBAI indices showed a moderate quarter-on-quarter retreat in the fourth quarter of 2025. This has been seen as the result of diminishing returns from front-loading activities, as well as from a more cautious approach to investment, financing, and capacity utilisation amid ongoing external uncertainties.The “current performance” index for business activity in Q4 retreated to 50.3 from 54.7 in the previous quarter, while the “expectations” index dropped to 51 from 55.7. Despite the drop, both indices remained in expansionary territory, indicating that GBA businesses still maintained a broadly positive outlook.Turning to the sub-indices, a mixed picture emerged for both “current performance” and “expectations” for the quarter overall. More specifically, with regard to “current performance”, the “new orders”, “fixed asset investment” and “profit” sub-indices all fell below the 50 watershed level. This, however, was seen as a correction following the end of the front-loading process in earlier quarters. Subdued growth in loans and fixed-asset investment in the Chinese Mainland also contributed to this slight downward trend.On the contrary, the “expectations” remained relatively positive, with sub-indices for “production/sales”, “new orders” and “profits” all staying in expansionary territory in the fourth quarter last year. Taken together, these upbeat outcomes suggest a strong likelihood that robust demand will persist through the first quarter of 2026 and beyond.In terms of individual GBA city evaluations, Hong Kong's readings were well above the survey average. This confirmed that the city’s economic rebound remained on course at year-end, with the “current performance” sub-index up 5.7 points to 57.9 and the “expectations” reading up 1.8 points to 55.4. Overall, this sustained recovery in growth momentum was attributed to the city’s “professional services” and “retail/wholesale” sectors.Wing Chu, Deputy Director of Research, HKTDC, said: “Following the extension of the trade truce between the US and China, business sentiment in Hong Kong continued to improve, allowing the city to outperform its peer cities across the GBA. This strength stands in contrast to the broader moderation seen in the overall GBA indices amid persistent external uncertainties. This momentum in Hong Kong's recovery is expected to remain intact, supported by buoyant business activity and the professional services sector's solid performance– key factors that underscore the city’s recovery trajectory. The HKTDC will continue to proactively support GBA enterprises in leveraging Hong Kong's professional services to ‘go global’ and capitalise on opportunities in emerging markets, including those in the Middle East.”In order to get a greater understanding of the wider aspirations of GBA businesses, the survey also examined their interest in the expansion into the Middle East. Encouragingly, over half of respondents (54.8%) expressed interest in expanding into the Middle East, with the UAE (53.9%) and Saudi Arabia (53.2%) selected as the top two priority markets.Digging deeper into these findings, of the companies that have already started or are interested in expanding into the Middle East, nearly 60% were engaged in trading/ distribution activity. This was followed by manufacturing (42.7%) and logistics/ storage (28.3%).Despite widespread optimism about emerging opportunities in the Middle East, many GBA businesses were also aware they faced several challenges in ensuring success. Overall, the top three concerns here were: “lack of understanding of local laws and regulations” (50.4%), “opaque local regulatory environment and restrictions on foreign investment” (43.1%) and “cultural and business differences” (42%).Crucially, to help manage such challenges, 99.2% of respondents saw Hong Kong’s world-class services as pivotal to the success of their Middle East expansion plans. Particular emphasis was placed on the decisive contribution of the city’s professional services sector, especially in successfully navigating local regulatory and compliance requirements.Hunter Chan, Economist, Greater China, Standard Chartered, said: “With increasingly complex geopolitical risks, global corporates not only actively diversify their supply chains but also explore new markets in recent years, thereby giving rise to numerous emerging trade corridors. The thematic survey found that the GBA corporates are interested in entering the Middle East, which aligns with Hong Kong Government’s policy focus to set up the ‘GoGlobal Task Force’ to leverage Hong Kong’s advantages as a ‘go global’ platform, and deepen economic ties with the Middle East. The survey also found that almost all respondents indicate that Hong Kong services are needed to help in expansion into the Middle East to address the challenges posed by local regulations and cultural differences. With its advantage in professional services, Hong Kong can further leverage its unique position as a ‘super-connector’, becoming a springboard for enterprises to develop overseas markets.”About the GBAIThe Standard Chartered Greater Bay Area Business Confidence Index (GBAI), jointly presented by Standard Chartered and Hong Kong Trade Development Council, is the first forward-looking quarterly survey in the market that examines business sentiment and synergistic effects in the Guangdong-Hong Kong-Macao Greater Bay Area ("Greater Bay Area" or "GBA"). The index is computed from the analysis of more than 1,000 responses from GBA companies regarding their overall operations, business environment, and expansion plans. The index includes five sub-indices that indicate business confidence for each industry, including manufacturing & trading, retail & wholesale, financial services, professional services, and innovation & technology. It enables investors and businesses to better understand the current business climate, gauge future performance and formulate their market strategies in the Greater Bay Area. The GBA Index is released quarterly in January, April, July, and October each year.Related materialsStandard Chartered GBA Business Confidence Index Report:https://www.sc.com/hk/gba/gba-index-report/HKTDC Research: https://research.hktdc.com/en/article/MjIzMTk3MzQwOAMedia enquiriesStandard Chartered Bank (Hong Kong) Limited, Corporate Affairs DepartmentFlora Chiu, Tel: +852 3843 2285, Email: flora.chiu@sc.com HKTDC Communications & Public Affairs Department:Katy Wong, Tel: +852 2584 4524, Email: katy.ky.wong@hktdc.orgClayton Lauw, Tel: +852 2584 4472, Email: clayton.y.lauw@hktdc.orgAbout Standard CharteredWe are a leading international banking group, with a presence in 54 of the world’s most dynamic markets. Our purpose is to drive commerce and prosperity through our unique diversity, and our heritage and values are expressed in our brand promise, here for good.Standard Chartered PLC is listed on the London and Hong Kong stock exchanges.The history of Standard Chartered in Hong Kong dates back to 1859. It is currently one of the Hong Kong SAR’s three note-issuing banks. Standard Chartered incorporated its Hong Kong business on 1 July 2004, and now operates as a licensed bank in Hong Kong under the name of Standard Chartered Bank (Hong Kong) Limited, a wholly owned subsidiary of Standard Chartered PLC.For more stories and expert opinions, please visit Insights at sc.com. Follow Standard Chartered on X, LinkedIn, Instagram and Facebook.About HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 29, 2026 - (ACN Newswire via SeaPRwire.com) – Quam Plus International Financial Limited ("Quam Plus Financial" or the "Group") is delighted to announce the successful conclusion of the "3rd Hong Kong Capital Markets Forum 2026" held at the Grand Hyatt Hong Kong. The Group is honored to be one of the Gold Sponsors of this prestigious event. Dr. Kenneth Lam, CEO of the Group, who also serves as Chairman of the Forum Organizing Committee cum Executive Deputy Chairman of The Chamber of Hong Kong Listed Companies (CHKLC), led a delegation of senior management to attend the forum. Mr. Xu Weigang, Director-General of the Economic Affairs Department of the Liaison Office of the Central People's Government in the HKSAR, and Mr. Paul Chan Mo-Po, GBM, GBS, MH, JP, Financial Secretary of the Government of HKSAR were also in attendance. Together with prominent figures from the capital markets, government, academia, and the financial sector, they engaged in in-depth discussions on further strengthening Hong Kong's economic momentum.The forum was jointly organized by Hong Kong Association of Registered Public Interest Entity Auditors Limited (PIEAA), The Chamber of Hong Kong Listed Companies (CHKLC), The Hong Kong Institute of Directors (HKIoD), and the Association of Hong Kong Capital Market Practitioners Limited (HKCMP), with strong support from key institutions including Hong Kong Exchanges and Clearing Limited (HKEX), the Securities and Futures Commission (SFC), and the Accounting and Financial Reporting Council (AFRC).As the global economy enters a new cycle of innovation and transformation, this year's forum, themed "Capturing the Next Growth Momentum” explored how Hong Kong can reinvent itself amid a rapidly changing international financial landscape, rebuild confidence, and transform challenges into powerful drivers of progress.Mr. Paul Chan Mo-Po, GBM, GBS, MH, JP, served as the Guest of Honour and delivered the keynote address. He stated: "In my view, the global environment is shifting in ways that create new and favourable opportunities for Hong Kong. Our challenge is how to seize the moment and deliver tangible outcomes. More specifically, that involves supporting the country's high-quality development; matching the needs of Mainland enterprises going global and the appetite of international investors; and, at the same time, driving Hong Kong's own growth."Dr. Kenneth Lam, in his capacity as Chairman of the Forum Organizing Committee, delivered the opening remarks: "As a vital financial hub connecting China and the world, our mission is to strengthen confidence, deepen integration, and expand diverse growth engines. We must keenly identify the next wave of growth drivers and ensure that markets advance in a balanced manner between flexibility and integrity. Positioned at the core of global transformation, this forum reminds us once again that progress is never accidental—it stems from resolute choices: with innovation as our aspiration, collaboration as our bridge, and conviction as our strength, we can lead Hong Kong forward and open up new chapters."Hong Kong now stands at the heart of global change. Advancing the capital markets requires not only visionary policies and regulation but also active participation and collaboration from all sectors. This year's forum focused on two key themes—digital asset development and capital market structural reform—examining how technological innovation can coexist with trust to drive reforms that build greater market resilience.As a proud Gold Sponsor of this year's forum, Quam Plus Financial looks forward to working hand in hand with all stakeholders, including central government offices in Hong Kong and other parties, to propel Hong Kong and the region toward new achievements. Together, we aim to seize new opportunities, activate new momentum, and march toward a high-quality, sustainable financial future.About Quam Plus International Financial LimitedQuam Plus International Financial Limited (Stock Code: 00952.HK) is a Hong Kong based financial services group which is listed on the Main Board of the Stock Exchange of Hong Kong Limited. The Company was publicly listed in Hong Kong in 1997, it is committed to building a comprehensive, full-licensed integrated financial platform. The core businesses of the Company are brokerage business, interest income business, corporate finance business, asset management business and investments and other businesses. The Company strives to become the ideal partner for both corporate and individual investors in Hong Kong and China. The Company also offers premier one-stop financial services to its clients. The Company continued to provide capital markets services through its representative office or the wholly-owned foreign enterprise in Shenzhen, Shanghai, Shenyang, Ningbo, Beijing, Chengdu, Hangzhou and Xiamen, PRC and through its Global Alliance Partners network and Oaklins International. Visit https://www.quamplus.com/en.For further information, please contact:Quam IR LimitedMandy Lo, Tel: (852) 2217-2753, Email: mandy.lo@quamgroup.comCharlie Chan, Tel: (852) 2217-2504, Email: charlie.chan@quamgroup.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TEC Japan marks its 25th anniversary with the recent refurbishment of its inaugural centre at Cerulean Towers.Profitability has tripled over the last two years, attracting significant interest from major tech and financial institutions.TEC Japan boasts an impressive occupancy rate of over 90%, with prime locations fully occupied, reflecting strong demand for premium workspaces.Photo: TEC Cerulean Towers CentreJAPAN, January 29, 2026 - (ACN Newswire via SeaPRwire.com) – The Executive Centre (“TEC”), the leading premium flexible workspace provider in Asia Pacific and the Middle East, proudly commemorates its 25th anniversary in Japan. Since the unveiling of its first centre at Cerulean Towers in 2001, TEC has established itself as a trusted partner in the business community and has expanded to 12 centres in Japan. To celebrate this significant milestone, the company hosted a special event on January 23, 2026, marking the completion of a comprehensive refurbishment to enhance the centre's offerings.Photo: TEC Cerulean Towers Reopening EventThe refurbishment of the Cerulean Tower facility epitomizes TEC’s commitment to long-term investment and reinvestment in its properties. Liam Owens, Regional Director of TEC Japan, stated, “Our legacy in Japan is built on 25 years of trust and reliability, and reflects a long-term commitment to the region. The five projects completed last year—three expansions and two refurbishments—highlight both our growth and our continued reinvestment in existing assets, reinforcing our dedication to long-standing partnerships with clients and landlords.”As TEC looks to the future, the company recognizes the vast potential of the Japanese market, envisioning a strategic expansion beyond Tokyo. “Japan represents not just a city market, but a burgeoning regional opportunity,” added Owens. “Our intent is to position TEC as a leader throughout the country, meeting the diverse needs of businesses across various sectors.”Photo: Liam Owens, Regional Director of TEC JapanIn the past two years, TEC Japan has experienced remarkable growth, tripling its profitability and attracting a wave of interest from leading tech and financial institutions. This surge indicates the wider market's recognition of Japan as an attractive location for business operations. With an overall occupancy rate exceeding 90%, TEC’s prime locations, particularly in the Tokyo Station area, are fully occupied, underscoring strong demand for its premium workspace solutions.As The Executive Centre celebrates its 25th anniversary in Japan, it remains steadfastly committed to innovation and excellence, looking forward to continued growth and service to its clients.About The Executive CentreThe Executive Centre (TEC) is a premium flexible workspace provider that opened its doors in Hong Kong in 1994 and has over 240 Centres in 37 cities across 15 markets.The Executive Centre caters to professionals and industry leaders. TEC has a global network spanning Greater China, Southeast Asia, North Asia, India, Sri Lanka, the Middle East, and Australia. Each Executive Centre offers a prestigious address with the advanced infrastructure to meet the needs of its Members.Privately owned and headquartered in Hong Kong, TEC provides Private and Shared Workspaces, Business Services, and Meeting & Events facilities to suit its clients’ business needs.www.executivecentre.comPress EnquiriesThe Executive CentrePebble Lee, Pebble_lee@executivecentre.com, +852 3951 9888 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com